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Restoring tissue oxygenation has the potential to improve poorly healing wounds
with impaired microvasculature. Compared with more established wound therapy
using hyperbaric oxygen chambers, topical oxygen therapy has lower cost and better
patient comfort, although topical devices have provided inconsistent results. To
provide controlled topical oxygen while minimizing moisture loss, a major issue for
topical oxygen, we have devised a novel wound bandage based on microfluidic
diffusion delivery of oxygen. In addition to modulating oxygen from 0 to 100% in 60
seconds rise time, the microfluidic oxygen bandage provides a conformal seal around
the wound. When 100% oxygen is delivered, it penetrates wound tissues as measured
in agar phantom and in vivo wounds. Using this microfluidic bandage, we applied the
oxygen modulation to 8 mm excisional wounds prepared on diabetic mice. Treatment
with the microfluidic bandage demonstrated improved collagen maturity in the
wound bed, although only marginal differences were observed in total collagen,
microvasculature, and external closure rates. Our results show that proper topical
oxygen can improve wound parameters underneath the surface. Because of the ease
of fabrication, the oxygen bandage represents an economical yet practical method for
oxygen wound research.
Oxygen is pervasive in wound healing processes and plays a
number of critical roles in inflammation, proliferation, and
tissue remodeling phases. During the initial inflammatory
phase, oxygen modulation in the forms of reactive oxygen
species and hypoxia signals leukocyte recruitment1–3 and
stimulates macrophage secretion of angiogenic factors,4–6
respectively. Hypoxia has been demonstrated to promote
keratinocyte migration,7,8 the key process in reepithelializa-
tion. Conversely, oxygen is critical to many steps of healing.
During the proliferative phase, oxygen promotes proliferation
and migration in fibroblast and endothelial cells,9–11 and
stimulates fibroblasts to lay down collagen to strengthen the
wound.12,13 Moreover, collagen maturation during the remod-
eling phase is an oxygen-intensive process.12,14 Disturbances
of these oxygen dynamics are implicated in poorly healing
wounds, including those found in diabetic individuals. Dia-
betic wounds with poor microvasculature and thus inadequate
tissue oxygenation have impaired fibroblast, endothelial pro-
liferation and function.15–17 These wounds show prolonged
inflammation, poor angiogenesis, and impaired collagen
maturity,18–20 leading to delayed closure and recurrence due to
inadequate strength of underlying tissue.21 Restoration of
proper oxygen dynamics has been suggested as a therapy to
improve the speed and maturity of healing in these wounds.
The most common therapeutic techniques to restore wound
oxygenation are the Hyperbaric Oxygen Therapy (HBOT)
and the Topical Oxygen Therapy (TOT). HBOT involves an
established protocol derived from hyperbaric chamber usage
in gas poisoning and decompression sickness, with clear
mechanisms of tissue oxygenation.22,23 However, HBOT sub-
jects the patient in a sealed and pressurized (2 to 3 atm)
oxygen environment, risking claustrophobia, ear damage, and
systemic neurotoxicity and oxidative damage.24 TOT, on the
other hand, is directly applied to the surface of the wound at
atmospheric pressure, typically through continuous oxygen
flow in a bladder device.25–28 TOT improves the cost, conve-
nience, and patient comfort during the wound therapy.
However, gas flow from TOT device convectively dries the
wound, a situation that might inhibit further oxygen diffu-
sion.29 Hence, creating a topical oxygen technique with mois-
ture control might improve oxygen delivery. Another
limitation of HBOT and TOT is that these methods cannot
achieve rapid gas level modulation due to the large amount of
gas volume to be exchanged. Both HBOT and TOT in their
current forms deliver a constant level of oxygen, e.g., 100%
without the temporal dynamics observed in real wounds. The
development of miniature oxygen bandages that allow con-
trolled oxygen delivery with rapid adjustment and moisture
control may resolve the therapeutic limitations of HBOT and
TOT in the treatment of wounds.
To demonstrate controlled oxygen therapy without convec-
tive drying, we employed microfluidic control of oxygen
similar to previously demonstrated techniques of modulating
oxygen via microfluidic gas channels.30–32 Using this technol-
ogy, we designed a microfluidic bandage that delivers oxygen
to the wound via diffusion only. The bandage, shown in
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Figure 1, is comprised of a microfluidic component embed-
ded in Tegaderm (3M, St. Paul MN) dressing adhesive. The
microfluidic component, fabricated from polydimethylsilox-
ane (PDMS), features (1) 300 mm wide microfluidic channels,
(2) two oxygen-filled chambers 10 mm in diameter, and (3)
100 mm thick gas-permeable PDMS membrane. The bandage
is designed to be connected to medical grade oxygen tanks
through the microchannels, filling up the oxygen chambers
and diffusing oxygen through the elastic membranes directly
to the wound. The elastic bandage provides localized oxygen
delivery that conforms to skin topology while minimizing
convective drying. Furthermore, the construction of a six-
celled cage allowed the simultaneous treatment of multiple
tethered animals while allowing them to roam freely
(Figure 1). Having an easy-to-apply oxygen bandage com-
bined with the ability to do treatments on multiple animals
represents a novel and useful technology for studying oxygen
effects in wound healing. With this goal in mind we demon-
strate here the design, fabrication, and validation of such




The microfluidic component of the oxygen bandage is a mul-
tilayer device comprised of a dome encapsulation layer, a
microfluidic layer, and a PDMS membrane layer from top to
bottom, shown in Figure 1B. The dome cap was formed by
pipetting 250 mL of premixed PDMS and dropping onto a
silicon wafer heated to 120 °C, allowing the droplet to form a
semispherical section before curing. The microfluidic chan-
nels were patterned by exposing UV light through a
computer-designed photomask (FineLine Imaging, Colorado
Springs, CO) onto 300 mm thick SU8 photoresist, and devel-
oping away the unexposed material. This pattern was trans-
ferred by pouring PDMS prepolymer over the SU8 and cured
at 90 °C for 2 hours. The membrane layer was made by
spinning PDMS on another silicon wafer at 800 rpm for 30
seconds, then curing at 85 °C for 5 minutes. After making all
three layers, appropriate access ports and 10 mm chambers
were punched, and the surface was treated with a corona
plasma device (Electro-Technic Products, Inc., Chicago, IL)
for 30 seconds prior to bonding. Aligned and bonded devices
were baked at 120 °C for 2 hours to further strengthen the
bonding. Finished devices were submerged under a water bath
and leak tested by flowing air through the device with a
syringe.
Oxygen bandage validations
To test the controlled, localized delivery of oxygen, the ban-
dages were placed against a fluorescence oxygen sensor and
imaged under an Olympus IX71 microscope. The oxygen
sensor was coated with ruthenium dye, whose fluorescence is
quenched by oxygen (Foxy-slides, Ocean Optics, Inc,
Dunedin, FL). Ten, 21, 60, and 100% oxygen was supplied to
the bandage, and the final diffused oxygen was measured over
time. To simulate proper sealing of oxygen delivery over
wound topology, a gas-permeable obstacle (5 mm round,
200 mm tall PDMS dome cap) was tested underneath two
types of bandages: a bandage with deformable membrane and
a bandage with rigidly supported membrane. Diffused oxygen
was measured underneath the obstacles and compared. Lastly,
oxygen penetration was tested with 3% agar gel, to simulate
skin diffusion. These phantom tissues were cut to 0.2 to 1 mm
thicknesses in 0.1 mm increments with a Vibratome (Series
1000 Classic, Ted Pella, Inc., Redding, CA) and sandwiched
between the bandage and sensor for characterization.
A B
C D
Figure 1. Microfluidic oxygen bandage:
(A) the microfluidic component of the
bandage is entirely PDMS, (B) the
microfluidics are comprised of multiple
layers, including microfluidic channels,
10 mm chambers with dome caps, and
a gas-permeable membrane, (C) diffu-
sion via this membrane provides
oxygen delivery without convective
flow, (D) up to six animals can be
treated simultaneously by mounting the
oxygen bandages with Tegaderm and
tethering them to a medical grade
oxygen tank.
Lo et al. Microfluidic oxygen bandage
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Animal protocol
All animal procedures followed University of Illinois guide-
lines for the humane treatment of animals and were approved
by the University of Illinois Institutional Animal Care and
Use Committee. To test the effects of microfluidic oxygen on
wounds, SKH1 hairless mice (Charles River Laboratories,
Wilmington, MA) were used, taking advantage of their skin
morphology for easy wound bandaging. Three groups of
normal, diabetic, and oxygen-treated diabetic animals were
used, as listed in Table 1. The last two groups were injected
with low-dose streptozotocin (STZ) at 50 mg/kg daily for 5
consecutive days, following detailed protocols at http://
www.diacomp.org. Diabetic animals were verified with a tail
pinch glucose test, at 200 mg/dL cutoff. Animals that did not
achieve this glucose level were treated again 7 weeks after the
first injection. The combined STZ induction rate was 80%.
All animals were 13 weeks old at the time of wounding.
Animals were anesthetized with 100/5 mg/kg ketamine/
xylaxine. The backs of the animals were cleaned with an
isopropyl alcohol wipe. Skin from the back was folded against
a rubber disk and wounds were prepared with an 8 mm cir-
cular biopsy punch, resulting in two full thickness wounds at
15 mm distance apart center to center. Oxygen bandages, with
or without oxygen flow, were fitted on all animals prior to
their waking. The wounds were followed for 14 days after
wounding. Pictures of the physical wounds were taken each
day before treatment. Animals were sacrificed at day 14 after
wounding, and tissue samples were used to prepare frozen
histologic section, paraffin embedded histologic section, and
collagen analysis via quantification of hydroxyproline.
Oxygen treatment protocol
All three animal groups were fitted with bandages, with 100%
oxygen tethered only to the treatment group. The other two
groups were in equilibrium with ambient air (21% oxygen)
and regarded as nondiabetic and diabetic controls. For the
treatment group, a six-celled cage was constructed for simul-
taneous treatment of the five animals, as shown in Figure 1D.
Plexiglass was cut and silicone-glued as divider inserts in a
2′x1.5′x1′ transparent plastic box. The lid was cut with
windows to allow tethered gas lines to access animals in the
cells. Food and water was supplied to each animal directly
and via a 15 mL test tube respectively. Gas lines were tethered
to the animals with a 360° freely rotating quick connect
coupler (Colder Products, St. Paul, MN). All tethered lines
were supplied through a flow adjustable manifold connected
to a single silicone line hooked up to a 697 L medical-grade
100% oxygen tank. Oxygen was supplied to the diabetic treat-
ment group 4 hours a day for 14 days starting immediately
after wounding. At the end of each treatment day, bandages
from all animal groups were removed, boiled for 5 minutes in
water, disinfected with alcohol wipes, and tested for leakage
in preparation for use the next day. Broken or leaky devices
were replaced with new ones.
In vivo tissue oxygen penetration quantification
To quantify the extent of wound oxygen penetration, we used
a fiber optic fluorescence oxygen probe (FOXY Probe, Ocean
Optics) to measure oxygen tension. This method allows direct
measurement of tissue oxygen penetrations across the entire
skin/wound thickness noninvasively. By inserting the fiber
optic probe beneath the skin and measuring before and after
100% oxygen was introduced, we recorded an elevated
oxygen tensions above the baseline. Days 3, 7, and 14 after
wounding were included as measurement time points.
Tissue tests and histology
Hydroxyproline analysis
The measurement of hydroxyproline is commonly used as a
relevant marker of total collagen content. Both normal and
wound tissues were harvested at day 14. Tissue samples were
weighed and hydrolyzed in 6 M HCl immediately after col-
lection and analyzed for hydroxyproline using a colorimetric
kit from QuickZyme Biosciences (Leiden, The Netherlands).
Standard solutions from 12.5 to 300 mM were included in the
assay, and samples were read in duplicates on a 96-well plate
at 570 nm in a plate reader (Molecular Devices, Sunnyvale,
CA).
Histologic assessment
To examine tissue vascularity, frozen sections were subjected
to immunohistochemical staining for CD31, a marker of
blood vessels, as previously described.33 Briefly 7 mm sec-
tions were cut from Optimal Cutting Temperature Compound
embedded specimens (Sakura Finetek USA Inc., Torrance,
CA), and then fixed in -20 °C acetone for 10 minutes. Sec-
tions were blocked with 10% goat serum for 30 minutes,
stained with primary rat anti-mouse CD31 (BD Pharmingen,
0.31 mg/mL) for 45 minutes, incubated with secondary Alexa
594 goat anti-rat IgG (2 mg/mL, Life Technologies, Grand
Island, NY) for 45 minutes in the dark, and mounted in 50%
glycerol on a microscope slide. CD31 positive staining under
fluorescent microscopy was quantified using Image J software
(National Institutes of Health, Bethesda, MD). For picrosirius
red staining, paraffin embedded samples were cut to 5 mm
thick, rehydrated, treated with phosphomolybdic acid at
Table 1. SKH1 mice groups prior to wound healing experiments
Normal Diabetic Diabetic + O2
n 5 5 5
Weight 24.5 + 3.1 g 25.2 + 1 g 24.0 + 0.8 g
Glucose 73.5  9.9 mg/dL 287  69 mg/dL 275  17 mg/dL
Errors are standard deviations.
Microfluidic oxygen bandage Lo et al.
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0.2%, stained with picrosirius red solution for 90 minutes,
washed in 70% ethanol, dehydrated and mounted in xylene on
a microscope slide. Picrosirius staining images were viewed
under polarized microscopy and quantified by dividing the
areas of the red fibers by those of the green, using automatic
measurement programs provided by Axio Vision software
(Carl Zeiss, Thornwood, NY).
Data analysis and statistics
For device characterization, n = 3 experiments were con-
ducted for Figures 2–5, in which errors were expressed as
standard deviations. For the animal experiments, each animal
produced two wounds; and each wound was cut directly in
half, producing four tissues, of which three were randomized
for the hydroxyproline, CD31, and picrosirius tests. For each
test, n = 5 wounds from different animals were used for each
condition in Figures 6–9, in which errors were expressed
as standard deviations. Individual analyses of variance
(ANOVA) were performed first to assess the group difference.
Post hoc pairwise comparisons by individual-samples t-test
(single sided) were then examined. Please note that multiple
comparisons adjustments were not performed for these analy-




Glucose levels of all three animal groups were monitored
during STZ induction and measured again prior to wounding.
All mice exhibited similar body weights of about 24–25 g.
The fasting glucose levels of normal animals were
73.5  9.9 mg/dL; levels for untreated and treated diabetic
mice measured 287  69 mg/dL and 275  17 mg/dL,
respectively. Following the STZ diabetes induction, animals
with glucose <200 mg/dL were not used for experiments.
Table 1 shows the number and characteristics of animals used
in the experiments.
Modulation of oxygen concentrations
The microfluidic oxygen delivery through the PDMS mem-
brane was characterized by perfusing the microfluidic chan-
nels with gases (10, 21, 60 or 100% oxygen) as shown in
Figure 2. Equilibration of all oxygen concentrations were
achieved in less than 1 minute.
Localization of oxygen delivery in nonconformal and
conformal devices
To demonstrate proper sealing of the oxygen bandage, the
conformal delivery of oxygen was characterized by diffusing
oxygen through a predefined obstacle (PDMS, 5 mm round
by 200 mm tall) underneath two types of oxygen bandages, as
shown in Figure 3A and B. One device had support channels
100 mm tall, referred to here as nonconformal bandage. The
other had a much taller chamber of 1 mm thick without
support pillars, allowing the membrane to deform around the
Figure 2. Multiple concentrations of oxygen—10, 21, 60, and
100%—can be delivered by the microfluidic oxygen bandage,
with time scales less than 60 seconds. Error bars denote
standard deviations, n = 3 experiments.
Figure 3. Oxygen delivery via confor-
mal bandage can provide better delivery
to a rough surface. Line A (blue) repre-
sents background measurements exter-
nal (point A) to the oxygen chamber
while line B (red) represents position
(point B) directly underneath the
obstacle. (A) Rigid membrane device
cannot provide sealing around an
obstacle (5 mm round, 200 mm tall), and
cannot deliver oxygen through the
obstacle, (B) Elastic membrane in
oxygen bandage seals around the
obstacle and provides 100% oxygen
delivery through the obstacle. Error bars
denote standard deviations, n = 3
experiments.
Lo et al. Microfluidic oxygen bandage
Wound Rep Reg (2013) 21 226–234 © 2013 by the Wound Healing Society 229
obstacle and referred to here as conformal bandage. For the
nonconformal bandage, the delivered 100% oxygen did not
increase the concentration underneath the obstacle, which
stayed close to background ambient levels at 22.61  0.44%
O2. On the other hand, the conformal device delivered and
raised the oxygen directly underneath the obstacle to
99.5  4.40% O2 at equilibrium. These results showed that
the conformal device provided better sealing around a rough
surface similar to normal wound topology.
Microfluidic oxygen penetration
The penetration of microfluidic oxygen delivery through
thicknesses of 3% agar phantom tissue (0.2–1.0 mm in 0.1
increments) over time was measured and displayed in
Figure 4. At each time point (1, 2, 3, 5, 10 minutes), as the
thickness, i.e., depth, of the phantom tissue increased, the
oxygen concentration through that depth decreased. However,
over time the oxygen at all depths equilibrated up to a final
concentration. After 10 minutes of 100% O2 delivery, concen-
tration across 0.8 mm thickness was 78  5% O2.
In vivo tissue oxygen penetration
The extent of wound oxygen penetration was measured using
the fiber optic oxygen probe. Without gas, baseline oxygen as
a combination of ambient diffusion and skin perfusion mea-
sured from 10 to 15% for all conditions except day 7 (scab-
bing with inconsistent and low oxygen permeability). With
100% oxygen delivered to the bandage, normal tissue and
wound tissues at days 3, 7, and 14 after wounding measured
20%, 70%, 10%, and 20%, respectively. This time-varying
penetration corresponds to thinner tissue shortly after wound-
ing, thicker and less permeable tissue as fibrin clot maturation
occurs at day 7, and a return to post-closure tissue that
resembles normal skin. In summary, measurements at days 3
and 14 showed that the oxygen bandage indeed delivered
significantly elevated (p = 0.025 and p = 0.006, respectively;
Figure 5) oxygen tensions to the wound tissues, while day 7
with mature fibrin clot did not, p = 0.423.
Wound closure
Preliminary results (data not shown) indicated that applica-
tion of a microfluidic bandage itself with no oxygen delivery
had no effect on normal wound closure. For the actual experi-
ment, wound area was used as the end point for each of the 14
time points. ANOVA did not reveal a significant group effect,
p = 0.43. As expected, diabetic wounds closed more slowly
than nondiabetic wounds (p = 0.09, CI = [-3.48, 15.46]), as
shown in Figure 6. No difference in closure rate was seen
between oxygen-treated and nontreated diabetic wounds,
p = 0.73.
Figure 4. Oxygen delivered by bandage can penetrate agar.
After 10 minutes of equilibration, oxygen can be elevated up to
80% across a 0.8 mm thick section of agar tissue phantom.
Error bars denotes standard deviations of three agar samples.
Figure 5. In vivo tissue oxygen penetration was quantified by
a fiber optic oxygen probe. By inserting the fiber optic probe
beneath the skin and measuring before and after 100%
oxygen was introduced, we recorded elevated oxygen ten-
sions of 20, 70, 10, and 20% for normal, days 3, 7, and 14 after
wounding tissues, respectively, compared with their baselines
(p = 0.121, p = 0.025, p = 0.423, and p = 0.006). Day 7, repre-
senting wounds with distinct scabs, gave inconsistent results
but showed overall low oxygen permeability. Error bars denote
standard deviations, n = 3 wounds.
Figure 6. Oxygen bandage treatment does not accelerate or
slow external wound closure in diabetic mice. Error bars
denote standard deviations, n = 5 wounds.
Microfluidic oxygen bandage Lo et al.
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CD31 quantification of angiogenesis
To examine the extent of angiogenesis beneath the surface of
the closing wound, quantification of CD31 staining was per-
formed on specimens derived at 14 days after wounding.
Measurements were done in the wound bed of the section.
ANOVA did not reveal a significant group effect, p = 0.19.
Higher levels of CD31 positive staining were seen in normal
wounds when compared with diabetic wounds (p = 0.036,
CI = [-0.11, 2.17]), as shown in Figure 7. CD31 staining was
marginally higher in oxygen-treated wounds but was not sig-
nificantly different between treated and nontreated diabetic
wounds, p = 0.83. Overall, the analysis of wound capillary
content suggested no significant influence of oxygen bandage
on angiogenesis in wounds of diabetic mice.
Hydroxyproline and collagen maturity
To examine the extent and maturity of collagen deposition
beneath the surface of the closing wound, hydroxyproline
quantification and picrosirius staining were done on tissues
harvested 14 days after wounding. Hydroxyproline was
assayed immediately after tissue harvest to quantify the total
amount of collagen deposited, without distinction of maturity.
ANOVA found a significant group effect, p = 0.000. Hydrox-
yproline quantification showed that at 14 days post wounding,
the total content of collagen compared with normal non-
wounded tissues was lower in all wounds, normal wounds
(p = 0.0023, CI = [-12.77, -3.30]), diabetic wounds
(p = 0.0047, CI = [-12.47, -2.39]), and treated diabetic
wounds (p = 0.0022, CI = [-14.09, -3.64]) as shown in
Figure 8. Furthermore, there was a marginal decrease in non-
wounded diabetic vs. normal tissue, (p = 0.06, CI = [-8.94,
1.28]). However, no statistical difference was seen between
any of the wounded samples.
Total collagen content does not provide a measure of col-
lagen maturity, a feature that is known to be critical to the
development of wound strength.35 To examine collagen matu-
rity, picrosirius red staining and analysis was performed.
Measurements were made in the wound bed of the section.
ANOVA revealed a significant group effect, p = 0.000. As
expected, the ratio of red (mature)to green (immature) fibers
under picrosirius red staining was higher in normal vs. non-
treated diabetic wounds (p = 0.0005, CI = [0.89, 1.73]) as
shown in Figure 9. Importantly, oxygen-treated diabetic
wounds exhibited significantly higher red to green ratios than
Figure 7. Staining shows extent of
angiogenesis in (A) nondiabetic, (B) dia-
betic, and (C) oxygen-treated diabetic
wounds with red color corresponding to
CD31 positive areas. (D) Nondiabetic
wounds have the same density of CD31
positive areas as unwounded skin while
diabetic nontreated wounds have lower
density, p = 0.036. Oxygen-treated dia-
betic wounds, though marginally higher
but not significantly different than the
other groups. Error bars depict standard
deviations, n = 5 wounds.
Figure 8. Hydroxyproline shows lower collagen content in
unwounded diabetic compared with normal skin (*p = 0.06).
All 14 days wounded skins have lower collagen content
(**p < 0.01) and are not statistically different from each other
(normal, diabetic, normal wound, diabetic wound, diabetic
wound treated with oxygen). Blue error bar denotes standard
deviation, n = 5 wounds.
Lo et al. Microfluidic oxygen bandage
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nontreated diabetic wounds (p = 0.0010, CI = [0.22, 0.70]).
While oxygen-treated wounds of diabetic mice showed
greater collagen maturity than untreated diabetic wounds, the
levels remained lower than those of wounds from normal
mice, (p = 0.0012, CI = [-1.30, -0.40]). These data suggest
collagen maturation, but not total collagen levels, is improved
by the oxygen bandages.
Limitations of the study
The characterization of the oxygen bandage’s effect on col-
lagen maturation is subject to several limitations. First, we
measured the oxygen transport through the tissue thickness
via FOXY probe, which is sensitive to both gaseous and
dissolved oxygen concentrations. Further histological tests,
e.g., using hypoxyprobe, could compliment the measurement
by showing tissue interactions with oxygen. Second, we used
collagen maturation in our circular wounds as an indirect
measure of tissue strength, as opposed to direct tensiometer
measurement, which requires a linear wound. This is because
diffusion is more symmetrical and predictable in a circular
geometry, compared with a linear one. Lastly, the histological
and tissue sample tests were done at day 14. Although this
timing is consistent with collagen remodeling in 8-mm
wounds, it could be complimented by additional dynamical
data from other time points. Despite these limitations, we
have demonstrated oxygen penetration across the tissue thick-
ness using the bandage, with a corresponding improvement in
wound collagen maturation.
DISCUSSION
Our studies describe the development of a novel oxygen
delivery method through the construction of a microfluidic
bandage. Prior to this oxygen bandage, the only means of
oxygen therapy for wounds are hyperbaric chamber and
topical bladders. The oxygen bandage through its diffusion
membrane delivers oxygen conformally to the wound without
convective drying or high pressure of previous devices. In
addition, unlike oxygen bladders, the boundary layer of
oxygen diffusion is eliminated due to its direct application to
the wound resulting in more thorough oxygenation. Because
of this ability we were able to see modulations in the wound
collagen maturity underneath the surface. Moreover, oxygen
bandages can be deployed with small medical grade gas
supply to provide portability and convenience compared with
hyperbaric chamber or topical oxygen bladders.
Using the bandage, we applied oxygen modulation to
8 mm diabetic murine wounds. Diabetic wounds are
hypoxic,19,36–39 and the larger wound size has longer closure,
which can better illustrate the improvements of wound
healing. Up to 70% (prior to day 7) oxygen can penetrate
across the wound thickness. External closure did not show
significant difference between oxygen-treated and nontreated
diabetic wounds. Similarly, CD31 staining showed marginal
but not significantly higher angiogenesis in oxygen-treated
diabetic wounds than nontreated ones. Although total content
of collagen was not significantly different among the three
groups, collagen maturity was significantly improved in
oxygen-treated diabetic wounds vs. nontreated ones. Collagen
maturation involves a transition from Type III to Type I fibers
and cross-linking of immature fibers, and has been shown to
be heavily dependent on oxygen partial pressure.12,14 Matura-
tion of collagen leads to stronger tissue strength, resulting in
a better healing wound that is less likely to reopen. Our results
demonstrate that the diffused oxygen does provide improved
healing underneath the epidermis in terms of collagen matu-
ration, notwithstanding the marginally different angiogenesis
and similar closure rates.
Beyond oxygen itself, one additional consideration is that
alternative procollagen and angiogenic pathways such as
Figure 9. Picrosirius staining of (A)
nondiabetic, (B) diabetic, and (C)
oxygen-treated diabetic wounds shows
the extent of collagen maturation, (D)
maturity, expressed as ratio of red to
green fibers, is lower in diabetic
wounds, *p = 0.0005, but improved
with oxygen-treated diabetic wounds,
**p = 0.0010. Unwounded skin has
much higher maturity ration at
9.1  4.2. White dashed line denotes
wound boundary. Blue error bars
denote standard deviations, n = 5
wounds.
Microfluidic oxygen bandage Lo et al.
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lactate signaling and/or growth factor production by infl-
ammatory cells may also be functioning.40 Despite being
associated with hypoxic conditions, recent studies on oxygen-
dependent lactate modulation of vascular endothelial growth
factor and collagen suggested that lactate participates in a
feed-forward amplification of wound healing cues. As lactate
is abundantly produced by inflammatory cells, it may be that
the oxygen bandage has evoked changes in the inflammatory
response, a situation that may have modulated angiogenesis
on top of hyperoxia-enhanced collagen synthesis, considering
the high oxygen penetration we measured at day 3.
Results using the oxygen bandage provide a comparison to
existing devices. HBOT wound therapy has shown improved
closure, more angiogenesis and collagen maturity. Its mecha-
nism is well-understood to include a systematic elevation of
oxygen tension in blood and plasma. On the other hand,
previous studies using TOT showed inconsistent effects. Our
results suggest that the localized, moisture-stable oxygen
bandage could deliver up to 70% (prior to day 7) oxygen
across the wound thickness and improve collagen maturation
underneath. Whether this effect involves elements of
epithelial-fibroblast cross talk remains to be examined. In any
case, because of the ease and scalability of the oxygen
bandage technique, larger studies that provide more informa-
tion about effective dosages and mechanisms of action can
now be conceived.
Future implementations of the oxygen bandages could
provide additional temporal modulation of oxygen through
the use of pneumatic valves.41 Additionally, the concept of
topical delivery through controlled diffusion can be applied to
other therapeutic agents well beyond oxygen. Cytokines,
growth factors, metabolic factors like lactate, and even cell-
laden hydrogels can be administered using microfluidic
mechanisms. Microfluidic bandages therefore provide a novel
delivery platform that will enable many future wound healing
experiments.
In summary, we have demonstrated a microfluidic oxygen
bandage that can be used to locally deliver oxygen to the
wounds. It can deliver oxygen concentrations from 0 to 100%
in 60 seconds rise time, providing conformal coverage to the
wound, and penetrate wound tissues as measured in agar
phantom and in vivo wounds. Treatment of murine diabetic
wounds with this microfluidic oxygen bandage improved
healing outcomes in the form of higher collagen maturity.
These findings suggest that the microfluidic oxygen bandage
may be a useful technique for studying poorly healing
wounds.
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